Prexton Therapeutics

M Ventures, the corporate venture capital arm of Merck KGaA which has been instrumental in developing over 80 companies, is to receive €600m from its parent to increase the number and size of its in

Denmark's mid-sized pharmaceutical company, Lundbeck Inc. , has moved its first-ever monoclonal antibody into clinical studies by taking the anti-alpha-synuclein antibody, Lu AF82422, into the clinic

With three exits and a looming IPO from its third fund generating an IRR of 65% and investors already getting back 60% of the money they committed in 2015, Forbion, the European life sciences venture

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in